# Autolus Therapeutics (AUTL) — Earnings

AUTL · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/autl/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | −$0.15 |
| EPS estimate | −$0.19 |
| EPS surprise | +22.80% |
| Revenue surprise | +18.49% |
| Revenue | $45.7M |
| Revenue estimate | $38.6M |
| Reported | Aug 11, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1730463/000173046326000123/autl-20260630.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/f49a9f20-985e-c184-2c6e-cedd3101a603.html) |

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Aug 11, 2026 | −$0.19 | −$0.15 | 22.80% | $38.6M | $45.7M |
| Q1 2026 | May 14, 2026 | −$0.25 | −$0.27 | -6.72% | $26.3M | $26.2M |
| Q4 2025 | Mar 27, 2026 | −$0.26 | −$0.34 | -30.82% | $23.9M | $24.3M |
| Q3 2025 | Nov 12, 2025 | −$0.21 | −$0.30 | -39.93% | $22.1M | $21.2M |
| Q2 2025 | Aug 12, 2025 | −$0.23 | −$0.18 | 21.94% | $13.2M | $20.9M |
| Q1 2025 | May 8, 2025 | −$0.24 | −$0.26 | -6.78% | $2.2M | $9.0M |
| Q4 2024 | Mar 20, 2025 | −$0.21 | −$0.09 | 56.27% | $2.9M | $29,000.00 |
| Q3 2024 | Nov 12, 2024 | −$0.21 | −$0.31 | -44.66% | $155,000.00 | — |
| Q2 2024 | Aug 8, 2024 | −$0.19 | −$0.22 | -13.11% | $93,750.00 | — |
| Q1 2024 | May 17, 2024 | −$0.08 | −$0.24 | -199.63% | $29.0M | $10.1M |
| Q4 2023 | Mar 14, 2024 | −$0.25 | −$0.44 | -73.98% | $358,400.00 | — |
| Q3 2023 | Nov 2, 2023 | −$0.25 | −$0.26 | -4.21% | $624,800.00 | $403,000.00 |
| Q2 2023 | Aug 3, 2023 | −$0.22 | −$0.26 | -16.33% | $136,500.00 | — |
| Q1 2023 | May 4, 2023 | −$0.27 | −$0.23 | 13.95% | $379,286.00 | $1.3M |
| Q4 2022 | Mar 7, 2023 | −$0.27 | −$0.25 | 8.79% | $11.2M | $3.8M |
| Q3 2022 | Nov 3, 2022 | −$0.47 | −$0.47 | 0.38% | $144,286.00 | $2.4M |
| Q2 2022 | Aug 4, 2022 | −$0.42 | −$0.46 | -9.52% | $240,556.00 | — |
| Q1 2022 | May 5, 2022 | −$0.49 | −$0.41 | 16.82% | $171,429.00 | $166,000.00 |
| Q4 2021 | Mar 10, 2022 | −$0.39 | −$0.51 | -32.26% | $6.6M | $180,000.00 |
| Q3 2021 | Nov 3, 2021 | −$0.51 | −$0.47 | 6.97% | $291,684.00 | $236,000.00 |

## Frequently Asked Questions

### When did Autolus Therapeutics (AUTL) last report earnings?

Autolus Therapeutics last reported on Aug 11, 2026, covering fiscal Q2 2026.

### Did AUTL beat earnings estimates?

Yes. Autolus Therapeutics reported EPS of −$0.15 for Q2 2026 against a −$0.19 estimate — a 22.80% beat.

### How much revenue did AUTL report last quarter?

Autolus Therapeutics reported $45.7M in revenue for Q2 2026, against a consensus estimate of $38.6M.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).